Radiotherapy for Rectal Cancer and Radiation-Induced Malignancies from Epidemiological and Dosimetric Data

被引:0
作者
Kachris, Stefanos [1 ]
Mazonakis, Michalis [2 ]
机构
[1] Univ Hosp Iraklion, Dept Radiat Oncol, Iraklion 71110, Greece
[2] Univ Crete, Fac Med, Dept Med Phys, Iraklion 71003, Greece
来源
APPLIED SCIENCES-BASEL | 2024年 / 14卷 / 24期
关键词
rectal cancer; radiotherapy; second malignancies; epidemiological data; dosimetry; INTENSITY-MODULATED RADIOTHERAPY; TOTAL MESORECTAL EXCISION; OUT-OF-FIELD; 2ND PRIMARY CANCERS; PREOPERATIVE RADIOTHERAPY; RANDOMIZED-TRIAL; ADJUVANT CHEMOTHERAPY; SECONDARY-CANCER; PHASE-II; POSTOPERATIVE CHEMORADIOTHERAPY;
D O I
10.3390/app142412063
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Preoperative or postoperative radiation therapy is broadly employed in patients with rectal carcinoma. Radiotherapy directs high-energy beams of ionizing radiation toward the tumor area to destroy cancer cells. High radiation doses are needed for cell killing. The radiation exposure of the healthy tissues/organs may lead to carcinogenesis. This study describes the evolving role of radiotherapy in rectal cancer management. The present report also reviews epidemiological and dosimetric studies related to the radiation-induced second malignancies from pelvic radiotherapy. Some epidemiological studies have concluded that the second-cancer risk in patients subjected to radiation therapy does not increase compared to unexposed rectal cancer patients. Other researchers found an elevated or a marginally increased probability for second-cancer induction. Dosimetric studies reported cancer risk estimates for critical organs or tissues in the near and far periphery of the treatment volume. Useful information about the effect of the treatment parameters such as the irradiation technique, photon beam energy, and fractionation schedule on the organ-specific second-cancer risk was derived from the dose data analysis. The knowledge of these effects is needed for the selection of the optimal treatment parameters enabling a reduction in the resultant risk of carcinogenesis.
引用
收藏
页数:14
相关论文
共 82 条
[11]   Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer [J].
Bujko, K. ;
Nowacki, M. P. ;
Nasierowska-Guttmejer, A. ;
Michalski, W. ;
Bebenek, M. ;
Kryj, M. .
BRITISH JOURNAL OF SURGERY, 2006, 93 (10) :1215-1223
[12]   Long-course oxaliplatin-based preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study [J].
Bujko, K. ;
Wyrwicz, L. ;
Rutkowski, A. ;
Malinowska, M. ;
Pietrzak, L. ;
Krynski, J. ;
Michalski, W. ;
Oledzki, J. ;
Kusnierz, J. ;
Zajac, L. ;
Bednarczyk, M. ;
Szczepkowski, M. ;
Tarnowski, W. ;
Kosakowska, E. ;
Zwolinski, J. ;
Winiarek, M. ;
Wisniowska, K. ;
Partycki, M. ;
Beczkowska, K. ;
Polkowski, W. ;
Stylinski, R. ;
Wierzbicki, R. ;
Bury, P. ;
Jankiewicz, M. ;
Paprota, K. ;
Lewicka, M. ;
Cisel, B. ;
Skorzewska, M. ;
Mielko, J. ;
Bebenek, M. ;
Maciejczyk, A. ;
Kapturkiewicz, B. ;
Dybko, A. ;
Hajac, L. ;
Wojnar, A. ;
Lesniak, T. ;
Zygulska, J. ;
Jantner, D. ;
Chudyba, E. ;
Zegarski, W. ;
Las-Jankowska, M. ;
Jankowski, M. ;
Kolodziejski, L. ;
Radkowski, A. ;
Zelazowska-Omiotek, U. ;
Czeremszynska, B. ;
Kepka, L. ;
Kolb-Sielecki, J. ;
Toczko, Z. ;
Fedorowicz, Z. .
ANNALS OF ONCOLOGY, 2016, 27 (05) :834-842
[13]   Dose Estimation by Geant4-Based Simulations for Cone-Beam CT Applications: A Systematic Review [J].
Cabanas, Ana M. ;
Arriagada-Benitez, Mauricio ;
Ubeda, Carlos ;
Meseguer-Ruiz, Oliver ;
Arce, Pedro .
APPLIED SCIENCES-BASEL, 2021, 11 (13)
[14]  
CAHAN WG, 1948, CANCER-AM CANCER SOC, V1, P3, DOI 10.1002/1097-0142(194805)1:1<3::AID-CNCR2820010103>3.0.CO
[15]  
2-7
[16]   A Population-Based Study of Secondary Prostate Cancer Risk after Radiotherapy in Male Patients with Rectal Cancer: A Retrospective Cohort Study [J].
Chuang, Jen-Pin ;
Lee, Yen-Chien ;
Lee, Jenq-Chang ;
Lu, Chin-Li ;
Li, Chung-Yi .
MEDICINA-LITHUANIA, 2019, 55 (04)
[17]   Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23) : a multicentre, randomised, open-label, phase 3 trial [J].
Conroy, Thierry ;
Bosset, Jean-Francois ;
Etienne, Pierre-Luc ;
Rio, Emmanuel ;
Francois, Eric ;
Mesgouez-Nebout, Nathalie ;
Vendrely, Veronique ;
Artignan, Xavier ;
Bouche, Olivier ;
Gargot, Dany ;
Boige, Valerie ;
Bonichon-Lamichhane, Nathalie ;
Louvet, Christophe ;
Morand, Clotilde ;
de la Fouchardiere, Christelle ;
Lamfichekh, Najib ;
Juzyna, Beata ;
Jouffroy-Zeller, Claire ;
Rullier, Eric ;
Marchal, Frederic ;
Gourgou, Sophie ;
Castan, Florence ;
Borg, Christophe .
LANCET ONCOLOGY, 2021, 22 (05) :702-715
[18]   Models for the risk of secondary cancers from radiation therapy [J].
Dasu, Alexandru ;
Toma-Dasu, Iuliana .
PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2017, 42 :232-238
[19]   Neoadjuvant PET and MRI-based intensity modulated radiotherapy leads to less toxicity and improved pathologic response rates in locally advanced rectal cancer [J].
David, John M. ;
Gresham, Gillian ;
Jabbour, Salma K. ;
Deek, Matthew ;
Thomassian, Shant ;
Robertson, John M. ;
Newman, Neil B. ;
Herman, Joseph M. ;
Osipov, Arsen ;
Kabolizadeh, Peyman ;
Tuli, Richard .
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 9 (04) :641-649
[20]   Impact of Age on Multimodality Treatment and Survival in Locally Advanced Rectal Cancer Patients [J].
De Nes, Lindsey C. F. ;
Heil, Thea C. ;
Verhoeven, Rob H. A. ;
Lemmens, Valery E. P. P. ;
Rutten, Harm J. ;
De Wilt, Johannes H. W. ;
Vissers, Pauline A. J. .
CANCERS, 2022, 14 (11)